Molecular Partners

Molecular Partners will in future concentrate on targeted radiopharmaceuticals for cancer treatment and plans to cut up to 55 positions (about 44%). The focus is the radio-DARPin candidate MP0712 against small-cell lung cancer (DLL3), which is being tested in a phase 1/2a study; initial safety data are expected in December 2026, efficacy data in 2027. Further radio-DARPin candidates (MP0714, MP0726, MP0730) are at various early stages of development. As of 30 September 2026 the company had CHF 57.5 million in cash, which under current planning should be sufficient into late 2027, although the financial effects of the restructuring remain uncertain. » Plus sur finanzen.net

Molecular Partners has selected MP0730 as its third program for targeted alpha radiotherapies. The candidate targets the protein CD70, which is commonly expressed in clear‑cell renal cell carcinoma and other tumors. In animal studies, MP0730 accumulated strongly and persistently in tumor tissue while causing low exposure in healthy organs. The first clinical study in humans is planned for the second half of 2027. » Plus sur finanzen.net

Molecular Partners reports an operating loss of CHF 27.0 million and a net loss of CHF 26.7 million for H1 2026, and cash and cash equivalents of CHF 67.9 million, which the company expects will fund it through the end of 2027. The phase‑1/2a study of the DLL3‑targeting radio‑DARPin MP0712 has reached the next therapeutic dose level (cohort 2, 105 MBq) and continues to recruit; initial clinical data are expected later in 2026, with more extensive efficacy data in 2027. CD70 has been selected as the next target for the RDT pipeline; the program is planned to enter the clinic in 2027. Other programs such as MP0317, MP0533 and MP0632 are continuing in early‑phase or preclinical development. » Plus sur finanzen.net